# Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases

> **NCT06311851** · PHASE1,PHASE2 · RECRUITING · sponsor: **Pardis Noor Medical Imaging and Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Cancer
- Metastatic Cancer
- Liver Metastases

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06311851
- **Lead sponsor:** Pardis Noor Medical Imaging and Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2026-03-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06311851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06311851, "Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06311851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*